SB-4826 for Solid Tumors and Non-Hodgkin Lymphomas
This study is testing a new drug called SB-4826 for adults with locally advanced or metastatic (spread to other parts of the body) solid tumors or non-Hodgkin lymphomas. The goal is to find the safest and most effective dose of SB-4826. For solid tumors, SB-4826 will be given alone. For non-Hodgkin lymphomas, it will be given alone or with rituximab, another cancer drug. Researchers will look at how well SB-4826 works and how your body handles the drug. This study is currently recruiting about 48 participants and is open to adults aged 18 and older.
- Study design
- This is a Phase 1/2 study that will involve increasing doses of SB-4826 to find a safe dose, followed by testing its effectiveness. It will include about 48 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure the effectiveness of SB-4826 after 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Peter Vu, MD · PRINCIPAL_INVESTIGATOR · University of California, San Diego
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Phase 1 (Dose-Escalation): Recommended phase 2 dose of SB-482621 days
To determine the recommended phase 2 dose of SB-4826, separately for each group. The recommended phase 2 dose will be the optimal biological dose based on consideration of safety (e.g., dose limiting toxicity, maximum tolerated dose, treatment-related adverse events) information together with all available pharmacokinetics, pharmacodynamics, and efficacy data. The recommend phase 2 dose will not exceed the maximum tolerated dose, which is the dose-level determined by the Bayesian Optimal Interval design with a target toxicity rate of 30% within the first 21 days.
- Phase 2 (Dose-Expansion/ Combination Therapy): Efficacy of SB-4826 at the recommended phase 2 dose.6 months
Objective response rate defined as the percentage of participants having a complete response or partial response within 6 months of the first dose of study therapy, as determined by investigator assessment per 2016 Lugano Classification criteria.